[早期弥漫性大B细胞淋巴瘤患者预后模型的比较]
[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
作者信息
Liu Weiping, Wang Xiaopei, Zhang Chen, Xie Yan, Lin Ningjing, Tu Meifeng, Ping Lingyan, Ying Zhitao, Deng Lijuan, Huang Huiying, Wu Meng, Sun Yingli, Du Tingting, Leng Xin, Ding Ning, Zheng Wen, Song Yuqin, Zhu Jun
机构信息
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) , Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):269-72. doi: 10.3760/cma.j.issn.0253-2727.2016.04.002.
OBJECTIVE
To compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).
METHODS
Early-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.
RESULTS
Ninety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.
CONCLUSION
NCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.
目的
比较不同模型对早期弥漫性大B细胞淋巴瘤（DLBCL）患者的预后价值。
方法
回顾性分析2000年1月至2012年12月诊断的早期DLBCL患者。所有患者均接受至少2个周期的免疫化疗R-CHOP方案（利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松），部分患者联合放疗。比较国际预后指数（IPI）、修订的IPI（R-IPI）和强化IPI（NCCN-IPI）的预后价值。
结果
本研究纳入97例早期DLBCL患者。中位年龄为58岁（15 - 88岁），中位随访时间为34.7个月（范围7.3 - 77.4个月）。全组患者预期5年总生存率（OS）为82%。根据IPI或NCCN-IPI，无患者处于高危组。根据IPI，低危、低中危、高中危组的5年OS分别为95%、38%和60%。根据R-IPI，预后非常好、好、差组的5年OS分别为93%、75%和60%。根据NCCN-IPI，低危、低中危、高中危组的5年OS分别为92%、85%和29%。
结论
NCCN-IPI对早期DLBCL患者是一个理想的预后模型。
Zotero 插件